OBJECTIVE: This cross-sectional study explored the association between carotid intima-media thickness (CIMT) and the oxidative stress markers asymmetric dimethylarginine (ADMA) and homocysteine in patients with end-stage renal disease who were on haemodialysis. METHODS: A total of 30 patients undergoing chronic haemodialysis treatment were recruited to this study. Homocysteine and ADMA levels were determined using a fluorescence polarization immunoassay and an enzyme-linked immunosorbent assay, respectively. CIMT was measured as a marker of atherosclerosis using highresolution ultrasonography and was performed after haemodialysis. RESULTS: Significant positive correlations were found between CIMT and ADMA, and CIMT and duration of haemodialysis. Linear regression analysis showed that ADMA level and age were significant independent determinants of CIMT, whereas homocysteine was not. CONCLUSIONS: The relationship demonstrated between plasma ADMA and carotid artery thickening suggests that ADMA may be a novel marker of atherosclerosis in patients on haemodialysis.
Introduction
At any stage of chronic renal failure, the cardiovascular (CV) mortality rate is very high. 1 -3 Over 50% of the deaths in patients with chronic renal failure can be attributed to cardiac events; this rate is between five and 20 times higher in these patients than that seen in the general population. 1 -3 Thus, current guidelines regard chronic renal failure as a coronary artery disease risk equivalent. 4 The underlying mechanism of CV mortality is not fully understood, but a combination of atherosclerosis and arteriosclerosis has been proposed. Arteriosclerosis describes alterations to the arterial wall that result from haemodynamic and humoral changes, whereas atherosclerosis is marked by the a These authors also work at Al-Irsyad Hospital, Surabaya, Indonesia.
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ADMA in end-stage renal disease existence of highly calcified plaques. 3, 5, 6 End-stage renal disease (ESRD) is defined as a loss of renal function requiring treatment with any form of chronic dialysis or transplantation. 2 Numerous traditional risk factors (including age, male sex, hypertension, diabetes, dyslipidaemia, cigarette smoking, obesity and a family history of coronary artery disease) have been proposed to explain the elevated CV risk in patients with chronic renal failure. 7 As these factors fail to account for the entire CV risk in patients with ESRD, other emerging risk factors (such as inflammation, oxidative stress, C-reactive protein, hyperhomocysteinaemia, nitric oxide availability, vascular calcification and stiffness, anaemia and haemodialysis) are being widely studied in these patients. 5 -13 Intervention based on these evolving CV risk factors may help to improve outcomes in ESRD patients.
Carotid artery intima-media thickness (CIMT), as measured by ultrasound, represents a marker of structural atherosclerosis that is also related to the atherosclerotic process in other arterial locations, including the coronary artery. 14, 15 In addition, an association has been demonstrated between increased CIMT and future myocardial infarction, stroke and CVrelated death. 16 Measurement of CIMT using B-mode ultrasonography has been shown to be reliable and reproducible. This noninvasive method can be used for both the initial evaluation and monitoring of atherosclerosis, 17 and has become well established as a measure of general atherosclerosis. 16 The intima-media thickness (IMT) of the carotid and femoral arteries is increased in uraemic patients, including patients who are not yet on maintenance haemodialysis. 18 Damage to large arteries associated with an increased IMT and arteriosclerosis has been shown to contribute to CV mortality in patients with ESRD. 19 The endogenous amino acid asymmetric dimethylarginine (ADMA) competitively inhibits nitric oxide synthase (NOS) 20 and, in vitro, inhibits isolated neuronal NOS more potently than isolated endothelial NOS. 21 ADMA reduces the activity of endothelial NOS, thereby altering the vascular structure and reactivity. Endothelial cells in injured vessels have high intracellular levels of ADMA, and endothelium dependent vasodilatation is impaired. 22, 23 ADMA may also inhibit the mobilization, differentiation and function of endothelial progenitor cells, which play an important role in the regeneration of injured endothelium and, therefore, in limiting the formation of atherosclerotic lesions. 24 A high ADMA level is considered to be an emerging CV risk factor in patients with ESRD: an increasing number of prospective clinical trials have shown that ADMA measurements can be used to identify individuals with a comparatively high probability of experiencing a major CV event. 25 The present study aimed to measure the CIMT, together with ADMA and homocysteine values, and to explore the association between CIMT and these oxidative stress markers in patients with ESRD who were on chronic haemodialysis.
Patients and methods

STUDY POPULATION
Consecutive patients with ESRD, with a creatinine clearance < 15 ml/min per 1.73 m 2 , who had been on chronic haemodialysis treatment for > 3 months, were recruited to this cross-sectional study. The study was conducted between October and December 2009 at Al-Irsyad Hospital, Surabaya, Indonesia. Patients who subsequently had a haemoglobin level < 8 g/dl or albumin level M Yusuf Alsagaff, M Thaha, M Aminuddin et al.
ADMA in end-stage renal disease < 3 g/dl, who were hospitalized for intensive treatment, or in whom data collection was inadequate, were excluded from the study. All patients underwent routine clinical assessments before the start of the study, which included history of diabetes, smoking, age, body mass index, duration of haemodialysis and blood pressure (BP) measurement. Hypertension was defined as systolic BP (SBP) ≥ 140 mmHg and diastolic BP (DBP) ≥ 90 mmHg, and/or taking antihypertensive drugs to maintain normal BP (< 120/80 mmHg). All patients gave written informed consent. The study protocol was approved by the Hospital Ethical Commitee of Al-Irsyad Hospital, and complied with the principles outlined in the Declaration of Helsinki.
DIALYSIS PROTOCOL
Each patient underwent dialysis twice per week for 4 weeks, with a F6-8 HPS polysulphone semi-synthetic dialyser (Fresenius, Bad Homburg, Germany). Each haemodialysis session lasted 4 h.
DETERMINATION OF OXIDATIVE STRESS MARKERS
For the determination of ADMA and homocysteine levels, venous blood samples (3 ml) were drawn from the arteriovenous fistula immediately before the first haemodialysis session each week. Serum was immediately separated from blood cells by centrifugation at 800 g for 15 min and stored at -20°C. The ADMA level was measured using an enzyme-linked immunosorbent assay (DLD Diagnostika, Hamburg, Germany), as previously described. 26 The plasma homocysteine concentration was measured using the AxSYM homocysteine fluorescence polarization immunoassay (Abbott Laboratories, Abbott Park, IL, USA), as previously described. 27, 28 
DETERMINATION OF CIMT
Measurements of the carotid artery were performed using high-resolution ultrasonography (Logiq ™ P5 ultrasound system; GE Healthcare, Chalfont St Giles, UK) with an 8L linear trapezoidal transducer (3.5 -10.5 MHz). All measurements were performed after the first haemodialysis session each week, by the same operator (M.Y.A.), who was blinded to the patient's oxidative stress marker status.
Each patient was examined in the supine position in a room with a low light level. Both carotid arteries were scanned at the level of the bifurcation of the common carotid arteries. CIMT was defined as the distance from the leading edge of the first echogenic line to the leading edge of the second echogenic line, with the image focused on the far wall of the artery. CIMT was measured using longitudinal antero lateral and posterolateral views of the distal common carotid arteries 0, 1 and 2 cm proximal to the carotid bifurcation during the diastolic phase. The mean value of all the CIMT measurements (all views on both sides) was recorded. 29, 30 
STATISTICAL ANALYSES
All statistical analyses were performed using the SPSS ® software package, version 17.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . Continuous variables were expressed as the mean ± SD. Pearson's correlation coefficient was used to analyse the relationship between the two oxidative stress markers and CIMT. Multiple linear regression analysis was used to define the independent determinants of CIMT. A P-value < 0.05 was considered to be statistically significant.
Results
A total of 46 patients with ESRD were initially recruited to the study; only 30 patients were in a stable clinical state throughout the study and had sufficient data for analysis. Clinical and demographic characteristics of these 30 patients are shown in Table 1 , together with the values for CIMT, ADMA and homocysteine.
There were positive correlations between CIMT and ADMA (r = 0.564, P = 0.001, Fig.  1) , and CIMT and duration of haemodialysis (r = 0.377, P = 0.040, Fig. 2 ). Although the mean homocysteine level was moderately increased ( Table 1 ) (normal range 6 -12 µmol/l), there was no correlation with ADMA or duration of haemodialysis.
Multiple linear regression analysis was performed. Using CIMT as the dependent variable, age, gender, hypertension, diabetes mellitus and duration of haemodialysis were incorporated into the model as independent variables, in addition to ADMA and homocysteine. The R 2 of the model was 0.62 with a P < 0.05. It revealed that ADMA and age were significantly and positively correlated with CIMT ( Table 2 ).
Discussion
In this study, associations between the specific oxidative stress markers ADMA or homocysteine, and the presence of vascular atherosclerosis (as determined by CIMT), were examined among haemodialysis patients. Studies have reported significant increases in CIMT among these patients, indicating that they have a higher risk of developing atherosclerotic disease compared with the general population. 17,18,31 -33 In contrast, in the present study, while ADMA level and duration of haemodialysis demonstrated significant positive correlations with CIMT, there was no significant correlation between homocysteine concentration and CIMT. Multiple logistic regression analysis showed a significant positive correlation between ADMA level and the CIMT, even when adjusted for other factors (e.g. homocysteine concentration, hypertension, duration of haemodialysis, diabetes mellitus and gender). Age was also an independent determinant of the CIMT.
Atherosclerosis arises as a result of endothelial vascular dysfunction and may, in turn, lead to further atherosclerotic processes. 34 -39 In the general population, endothelilal dysfunction is related to ADMA -an endogenous inhibitor of NOS. 40 Traditional CV risk factors, such as hypertension, dyslipidaemia and smoking, contribute to atherosclerosis and have also been shown to cause endothelial dysfunction. Furthermore, the coexistence of these traditional CV risk factors has an additive effect on the development of atherosclerosis. 7 The management of these factors results in an improvement in endothelial function and a reduced risk of CV mortality. Although the exact pathophysiological mechanisms have not been fully explained, there is a clear correlation between endothelial dysfunction and the risk factors for atherosclerosis. 41 -45 Thus, the mechanisms behind this dysfunction are of major interest. The discovery of ADMA and data showing its effect on NOS (both in vivo and in vitro) has led to many studies on its potential role in other clinical conditions where endothelial dysfunction is a common feature. 46 The level of ADMA in an individual is related to the extent of atherosclerotic vascular disease. 47 Schulze et al. 47 reported that the ADMA level has the best discriminative power in differentiating patients with coronary heart disease from healthy individuals. In a multivariate model, ADMA was a positive predictor with an odds ratio of 6.04 (95% CI 2.56, 14.25) for those in the highest tertile of ADMA versus the lowest. 47 Interestingly, the ADMA level has also been shown to be associated with coronary lesions in angiography; higher concentrations of ADMA were found distal to lesions rather than proximal to them. 48, 49 As documented in experimental and clinical studies, the kidney has a unique role in the nitric oxide/ADMA pathway. Over the last 15 years, an increasing number of studies have suggested the involvement of ADMA in several alterations of uraemic state. Thus, ADMA is considered to be a "uraemic toxin". 50 The concentration of ADMA increases early in the course of chronic renal failure, earlier than the reduction in the glomerular filtration rate. 51 The increase in ADMA in the uraemic state is not fully explained. 52, 53 Another possible explanation would be the impairment of dimethylarginine dimethylaminohydrolase, an enzyme that metabolizes ADMA. 52, 54 Several studies have reported the endogenous inhibitor of NOS as the cause of endothelial dysfunction in patients with chronic renal failure. 55 -57 Both in the general population and in ESRD patients, the plasma level of ADMA is associated with thickening of the carotid artery, 58, 59 and with left ventricle hypertrophy. 60 These vascular and structural pathological findings are indicative of adverse CV events, as suggested in studies relating plasma level of ADMA to mortality. 61 -64 Increasing evidence from numerous prospective clinical trials also suggest that ADMA could be used to differentiate patients with CV disease from healthy individuals, and to discriminate between individuals within a group of patients with similar CV risk who are considered as having a homogenous risk profile. 25 A correlation between ADMA level and CIMT was observed in haemodialysis patients in the present study. ADMA was shown to be an independent risk factor for CIMT, indicating that ADMA is a potential CV risk factor in ESRD. Currently, it is unknown whether lowering the ADMA level would be of any clinical value, although numerous studies are trying to resolve this issue.
The main limitations of the present study were the small sample size and its crosssectional nature. These factors may explain why no significant correlation was found between plasma ADMA level and several other risk factors such as diabetes mellitus, hypertension and homocysteine concentration.
In conclusion, the present study demonstrated a relationship between plasma ADMA level and carotid artery thickening in haemodialysis patients, while other risk factors did not show such an association. These results suggest that ADMA may be a potential novel marker of atherosclerosis in patients on haemodialysis.
